Document Detail

Anti-mullerian hormone as a predictive marker for the selection of women for oocyte in vitro maturation treatment.
MedLine Citation:
PMID:  21671163     Owner:  NLM     Status:  MEDLINE    
PURPOSE: In oocyte in-vitro maturation (IVM) treatments, the chances to achieve a pregnancy are critically dependent on the retrieval of a suitable number of oocytes. In this study, we assessed the ability of circulating levels of anti-mullerian hormone (AMH) to identify normo-ovulatory women suitable for IVM treatment on the basis of the number of retrieved oocytes.
METHOD: Serum AMH was quantified in normo-ovulatory women younger than 39 years undergoing IVM treatment. After immature oocyte retrieval and IVM, maximum 3 mature oocytes were used for treatment and all resulting embryos were transferred, as established by law. From 177 cycles, 991 oocytes were recovered. Following IVM, 484 mature oocytes were obtained (50.1%).
RESULTS: The overall pregnancy rate per embryo transfer was 16.6% (25/151) and the implantation rate was 10.9% (30/278). Linear regression and receiver operating characteristic (ROC) analyses were applied to identify independent variables and quantify a cut-off AMH value able to identify patients suitable for IVM treatment. An AMH value of 1.28 ng/ml was identified as a threshold for the prediction of the retrieval of at least 5 oocytes, with a sensitivity of 93.4% and a specificity of 33.8%. Positive and negative predictive values were 67.6% and 75.0%, respectively.
CONCLUSIONS: AMH can be adopted to identify women candidate for an IVM treatment from whom a suitable number of oocytes may be retrieved. This is of crucial significance during a non-stimulated cycle, in order to prevent an insufficient oocyte collection and rescue the treatment by implementing a conventional controlled ovarian stimulation.
Rubens Fadini; Ruggero Comi; Mario Mignini Renzini; Giovanni Coticchio; Marilena Crippa; Elena De Ponti; Mariabeatrice Dal Canto
Related Documents :
1610333 - Analysis of accidents during instrument approaches.
24647593 - Air pollution exposure and adverse pregnancy outcomes in a large uk birth cohort: use o...
3840333 - Amniotic fluid prolactin and fetal lung maturation.
Publication Detail:
Type:  Journal Article     Date:  2011-06-15
Journal Detail:
Title:  Journal of assisted reproduction and genetics     Volume:  28     ISSN:  1573-7330     ISO Abbreviation:  J. Assist. Reprod. Genet.     Publication Date:  2011 Jun 
Date Detail:
Created Date:  2011-08-19     Completed Date:  2011-12-14     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  9206495     Medline TA:  J Assist Reprod Genet     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  501-8     Citation Subset:  IM    
BIOGENESI, Reproductive Medicine Centre, Istituti Clinici Zucchi, Via Zucchi 24, 20052, Monza, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anti-Mullerian Hormone / blood*
Biological Markers / blood
Embryo Transfer / methods
Estradiol / administration & dosage,  therapeutic use
In Vitro Oocyte Maturation Techniques / methods*
Oocytes / growth & development*
Ovulation Prediction / methods*
Reg. No./Substance:
0/Biological Markers; 50-28-2/Estradiol; 80497-65-0/Anti-Mullerian Hormone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Advances in Epigenetics and Epigenomics for Neurodegenerative Diseases.
Next Document:  Perioperative care of the infant with single ventricle physiology.